Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-545

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pemetrexed For Injection 750mg Label (Image 01)

Pemetrexed For Injection 750mg Label (Image 01)
Pemetrexed 750 mg/vial injection label for intravenous use, lyophilized powder for solution. The single-dose vial contains pemetrexed disodium equivalent to 750 mg pemetrexed. Manufactured by Gland Pharma Limited, India, and labeled for BluePoint Laboratories. Storage instructions and other regulatory information are also displayed.*
FDA Label Image

Pemetrexed For Injection 750mg Carton (Image 02)

Pemetrexed For Injection 750mg Carton (Image 02)
Packaging label for Pemetrexed injection, USP 750 mg/vial, lyophilized powder for intravenous use by BluePoint Laboratories. The label indicates it is a single-dose vial, cytotoxic agent, with storage and administration instructions. Includes manufacturer details and barcode.*
FDA Label Image

Structure (Image 03)

Structure (Image 03)
Chemical structure of pemetrexed disodium, depicted as a molecular diagram showing atom connectivity and specific functional groups, including nitrogen-containing rings and carboxylate groups with sodium ions and water of crystallization.*
FDA Label Image

Figure 1 (Image 04)

Figure 1 (Image 04)
A survival curve chart displaying overall survival percentages over time in months for two treatment arms labeled P+P+C and P+C. The chart includes a line graph with corresponding survival data points and a table presenting the number of patients at risk at various time intervals for each treatment arm.*
FDA Label Image

Figure 2 (Image 05)

Figure 2 (Image 05)
A survival probability line graph comparing Pemetrexed plus Cisplatin (PC) with Gemcitabine plus Cisplatin (GC) over 30 months. The x-axis shows survival time in months, and the y-axis shows survival probability. The graph includes patient counts at risk below the x-axis for both treatment groups across various time points.*
FDA Label Image

Figure 3 (Image 06)

Figure 3 (Image 06)
A Kaplan-Meier survival curve comparing survival probability over time (up to 30 months) for two treatment groups: Pemetrexed plus Cisplatin and Gemcitabine plus Cisplatin. The graph includes a table below showing the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 4 (Image 07)

Figure 4 (Image 07)
A survival curve chart comparing survival probability over time (in months) between two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). The chart includes a risk table showing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 5 (Image 08)

Figure 5 (Image 08)
A survival probability curve chart comparing Pemetrexed and placebo over survival time in months. The x-axis shows survival time from 0 to 42 months, and the y-axis shows survival probability from 0.0 to 1.0. Two lines represent survival: a solid line for Pemetrexed and a dotted line for placebo.*
FDA Label Image

Figure 6 (Image 09)

Figure 6 (Image 09)
A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between Pemetrexed and placebo. The solid line represents Pemetrexed, and the dotted line represents placebo. Below the x-axis, a table lists the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 7 (Image 10)

Figure 7 (Image 10)
A survival curve chart showing survival probability over time in months, comparing Pemetrexed and Placebo groups. The x-axis represents survival time in months up to 42, and the y-axis shows survival probability from 0 to 1. A table below the chart lists the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 8 (Image 11)

Figure 8 (Image 11)
A survival probability chart comparing Pemetrexed injection to placebo over 36 months. The x-axis shows survival time in months and the y-axis shows survival probability. Two lines represent Pemetrexed and placebo, with Pemetrexed showing higher survival probabilities over time. Below the graph, a table indicates the number of patients at risk for both groups over various time points.*
FDA Label Image

Figure 9 (Image 12)

Figure 9 (Image 12)
A survival probability Kaplan-Meier curve comparing Pemetrexed plus Cisplatin versus Cisplatin alone over survival time in months. The graph shows higher survival probability for the combination treatment with patients at risk detailed in a table below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.